Small intestinal bacterial overgrowth syndrome (SIBO) - clinical manifestations, diagnosis and therapeutic options
DOI:
https://doi.org/10.12775/QS.2024.22.51727Keywords
SIBO, small intestinal bacterial proliferative syndrome, microbiota, dysbiosisAbstract
Small intestine bacterial overgrowth (SIBO) is a gastrointestinal disorder characterized by an abnormal growth of bacterial populations within the small intestine. These conditions disrupt the balance of microorganisms in the gastrointestinal tract, leading to a variety of clinical symptoms and complications.
Excessive bacterial proliferation in the small intestine often results from impaired motility, anatomical abnormalities or changes in the immune system. These factors contribute to the fermentation of undecomposed carbohydrates, leading to the production of gasses and toxic by-products, causing symptoms such as abdominal pain, bloating, diarrhea and malabsorption. A variety of diagnostic methods, including breath tests and small bowel aspirate cultures, are used to accurately identify excessive bacterial growth. Treatment of SIBO involves a multidisciplinary approach, including dietary modifications, antibiotic therapy and prokinetic agents. Antibiotic treatment remains the cornerstone of therapy, but relapses require a focus on identifying and eliminating predisposing factors.
References
Okuniewicz R, Moos Ł, Brzoza Z. Small bowel bacterial overgrowth syndrome. Advances in microbiology 2021; 60(3): 203–210.
Singh RK, Chang HW, Yan D, et al. Influence of diet on the gut microbiome and implications for human health. J. Transl. Med. 2017; 15(1): 73.
Bushyhead D, Quigley EMM. Small intestinal bacterial overgrowth-pathophysiology and Its implications for definition and management. Gastroenterology 2022; 163(3): 593-607.
Wielgosz-Grochowska JP, Domanski N, Drywień ME. Efficacy of an irritable bowel syndrome diet in the treatment of small intestinal bacterial overgrowth: a narrative review. Nutrients 2022; 14(16): 3382.
Gąsiorowska J, Czerwionka-Szaflarska M. Small intestinal bacterial overgrowth syndrome versus irritable bowel syndrome. Przegl. Gastroenterol. 2013; 8(3): 165-171.
Skrzydło-Radomańska B, Cukrowska B. How to recognize and treat small intestinal bacterial overgrowth? J. Clin. Med. 2022; 11(20): 6017.
Krajicek EJ, Hansel SL. Small intestinal bacterial overgrowth: a primary care review. Mayo Clin. Proc. 2016; 91(12): 1828-1833.
Liu Chen Kiow J, Bellila R, Therrien A, et al. Predictors of small intestinal bacterial overgrowth in symptomatic patients referred for breath testing. J Clin Med Res. 2020; 12(10):655-661.
Erdogan A, Rao SS, Gulley D, et al. Small intestinal bacterial overgrowth: duodenal aspiration vs glucose breath test. Neurogastroenterol Motil. 2015; 27(4): 481-489.
Choung RS, Ruff KC, Malhotra A, et al. Clinical predictors of small intestinal bacterial overgrowth by duodenal aspirate culture. Aliment Pharmacol Ther. 2011; 33(9): 1059-1067.
Rao SSC, Bhagatwala J. Small intestinal bacterial overgrowth: clinical features and therapeutic management. Clin Transl Gastroenterol. 2019; 10(10): e00078.
Di Stefano M, Veneto G, Malservisi S, et al. Small intestine bacterial overgrowth and metabolic bone disease. Dig. Dis. Sci. 2001; 46(5): 1077-1082.
Bohm M, Siwiec RM, Wo JM. Diagnosis and management of small intestinal bacterial overgrowth. Nutr. Clin. Pract. 2013; 8(3): 289-299.
Avelar Rodriguez D, Ryan PM, Toro Monjaraz EM, et al. Small intestinal bacterial overgrowth in children: a state-of-the-art review. Front Pediatr. 2019; 7: 363.
Rezaie A, Buresi M, Lembo A, et al. Hydrogen and Methane-Based Breath Testing in Gastrointestinal Disorders: The North American Consensus. Am J Gastroenterol. 2017; 112(5): 775-784.
Romagnuolo J, Schiller D, Bailey RJ. Using breath tests wisely in a gastroenterology practice: an evidence-based review of indications and pitfalls in interpretation. Am J Gastroenterol. 2002; 97(5): 1113-1126.
Hoog CM, Lindberg G, Sjoqvist U. Findings in patients with chronic intestinal dysmotility investigated by capsule endoscopy. BMC Gastroenterol. 2007; 18; 7: 29.
Litwiniuk M, Zaniuk M, Hurkała K, et al. Treatment of small intestinal bacterial overgrowth: conventional antibiotic therapy and alternative therapy - probiotics and low FODMAP diet. Journal of Education, Health and Sport 2023; 41(1): 57-69.
Lauritano EC, Gabrielli M, Scarpellini E, et al. Small intestinal bacterial overgrowth recurrence after antibiotic therapy. Am. J. Gastroenterol. 2008; 103(8): 2031-2035.
Ghoshal UC, Shukla R, Ghoshal U. Small intestinal bacterial overgrowth and irritable bowel syndrome: a bridge between functional organic dichotomy. Gut Liver 2017, 11(2): 196-208.
Pandey KR, Naik SR, Vakil BV. Probiotics, prebiotics and synbiotics—a review. J. Food Sci. Technol. 2015; 52(12): 7577-7587.
Jalanka J, Major G, Murray K, et al. The effect of psyllium husk on intestinal microbiota in constipated patients and healthy controls. Int. J. Mol. Sci. 2019; 20(2): 433.
García-Collinot G, Madrigal-Santillán EO, Martínez-Bencomo MA, et al. Effectiveness of Saccharomyces Boulardii and metronidazole for small intestinal bacterial overgrowth in systemic sclerosis. Dig. Dis. Sci. 2020; 65(4): 1134-1143.
Holscher HD, Bauer LL, Gourineni V et al. Inulin supplementation affects the fecal microbiota of healthy adults participating in a randomized, double-blind, placebo-controlled, crossover trial. J. Nutr. 2015; 145(9): 2025-2032.
Saffouri GB, Shields-Cutler RR, Chen J, et al. Small intestinal microbial dysbiosis underlies symptoms associated with functional gastrointestinal disorders. Nat. Commun. 2019; 10(1): 2012.
Maccaferri S, Vitali B, Klinder A, et al. Rifaximin modulates the colonic microbiota of patients with Crohn's disease: an in vitro approach using a continuous culture colonic model system. J Antimicrob Chemother. 2010; 65(12): 2556-2565.
McIntosh K, Reed DE, Schneider T, et al. FODMAPs alter symptoms and metabolism of patients with IBS: a randomised controlled trial. Gut 2017; 66(7): 1241-1251.
Jacobs C, Coss Adame E, Attaluri A, et al. Dysmotility and proton pump inhibitor use are independent risk factors for small intestinal bacterial and/or fungal overgrowth. Aliment. Pharmacol. Ther. 2013; 37(11): 1103-1111.
Bubnov RV, Babenko LP, Lazarenko LM, et al. Specific properties of probiotic strains: relevance and benefits for the host. EPMA J. 2018; 9(2): 205-223.
Ojetti V, Petruzziello C, Migneco A, et al. Effect of Lactobacillus Reuteri (DSM 17938) on methane production in patients affected by functional constipation: a retrospective study. Eur. Rev. Med. Pharmacol. Sci. 2017; 21(7): 1702-1708.
Efremova I, Maslennikov R, Poluektova E, et al. Epidemiology of small intestinal bacterial overgrowth. World J Gastroenterol. 2023; 29(22): 3400-3421.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Krzysztof Dobrzeniecki, Natalia Olesińska, Magdalena Pachla, Aleksandra Grzegorczyk, Katarzyna Muc, Natalia Hopej, Kacper Turek

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 678
Number of citations: 0